---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-114496"
form_type: "8-K"
ticker: "OSRH"
cik: "0001840425"
company_name: "OSR Holdings, Inc."
filed_at: "2025-11-25T23:59:59+00:00"
generated_at: "2026-05-16T17:02:08.946639+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# OSR Holdings subsidiary Vaximm enters term sheet with BCM Europe for VXM01 license; $20M upfront, up to $815M milestones

## Summary
- Non-binding term sheet with BCM Europe AG for exclusive global license of VXM01 oral cancer immunotherapy.
- Potential $20M upfront payment plus up to $815M in clinical, regulatory, and commercial milestones.
- Six-month exclusivity period for negotiations; due diligence and board approvals required.
- BCM Europe is OSRH's largest shareholder; deal includes optional blockchain-based royalty mechanism (TAC tokens).
- Vaximm retains IP ownership; definitive agreement would grant BCME exclusive global rights.

## SEC filing metadata
- accession: 0001213900-25-114496
- form_type: 8-K
- ticker: OSRH
- cik: 0001840425
- company_name: OSR Holdings, Inc.
- filed_at: 2025-11-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840425/000121390025114496/0001213900-25-114496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840425/000121390025114496/ea0267127-8k_osrhold.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-114496
- JSON: https://secwatch.observer/filing/0001213900-25-114496.json
- Plain text: https://secwatch.observer/filing/0001213900-25-114496.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.